Ningbo Menovo Pharmaceutical Co., Ltd.

603538

CNE100002Y25

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-09 EDT			5-day change	1st Jan Change
14.37 ^CNY	-2.44%		+4.13%	-24.84%

04-29	Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-29	Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Ningbo Menovo Pharmaceutical Co., Ltd. cancelled the transaction announced on July 20, 2023

April 15, 2024

On April 16, 2024, Ningbo Menovo Pharmaceutical Co., Ltd. cancelled the transaction.

Latest news about Ningbo Menovo Pharmaceutical Co., Ltd.

Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Menovo Pharmaceutical Unit Gets Approval to Register Vildagliptin Tablets	04-23	MT
Ningbo Menovo Pharmaceutical Co., Ltd. cancelled the transaction announced on July 20, 2023	04-15	CI
Menovo Pharma's Unit Gets Nod to Market Clopidogrel Hydrogen Sulfate Tablets	03-06	MT
Menovo Pharma Gets Nod to Market Raw Drug Ingredient for Hypertension Into EU Market; Shares Up 3%	03-04	MT
Ningbo Menovo Pharmaceutical Co., Ltd.(XSSC:603538) dropped from S&P Global BMI Index	12-18	CI
Ningbo Menovo Pharma Registers Seizure Drug in China	12-05	MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Menovo Pharmaceutical Unit's Rosuvastatin Calcium Passes Drug Regulator's Technical Review	23-10-11	MT
Ningbo Menovo Pharmaceutical Co., Ltd.(XSSC:603538) added to S&P Global BMI Index	23-09-18	CI
Ningbo Menovo Pharma Registers Blood Pressure Drug	23-09-06	MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Ningbo Menovo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 652 million in funding from Ningbo Menovo Holding Group Co., Ltd. and other investors	23-07-19	CI
Ningbo Menovo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 651.999948 million in funding from Ningbo Menovo Holding Group Co., Ltd. and other investors.	23-07-19	CI
Ningbo Menovo Pharmaceutical Co., Ltd. announced that it expects to receive funding from Ningbo Menovo Holding Group Co., Ltd.	23-07-19	CI
Ningbo Menovo Pharmaceutical Co., Ltd. cancelled the transaction announced on August 15, 2022	23-07-19	CI
Menovo Pharmaceutical's Unit Gets Nod to Own Olmesartan Medoxomil Tablets	23-07-14	MT
Menovo Pharma Gets European Certification for Diet Drug	23-06-08	MT
Menovo Pharma Gets Registration Certificate for Moxifloxacin Hydrochloride Tablets	23-05-25	MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Menovo Pharma Unit's Diet Control Drug Passes Regulator Evaluation	22-12-20	MT
Menovo Pharma's API Obtains European Certificate	22-12-16	MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-14	CI
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-15	CI

Chart Ningbo Menovo Pharmaceutical Co., Ltd.

Duration

Period

Chart Ningbo Menovo Pharmaceutical Co., Ltd.

More charts

Ningbo Menovo Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of special active pharmaceutical ingredients (APIs) and medical intermediates. The Companyâs products contain gastropathic medicine and cardiovascular medicine, which include anti-hypertension medicine, anti-hyperlipidemia medicine and anti-thrombus medicine. The Company distributes its products to both domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Ningbo Menovo Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.37

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NINGBO MENOVO PHARMACEUTICAL CO., LTD.	-24.84%	435M
ELI LILLY AND COMPANY	+32.36%	695B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	361B
MERCK & CO., INC.	+19.46%	330B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+17.06%	239B
NOVARTIS AG	+8.07%	204B
ROCHE HOLDING AG	-7.73%	198B
AMGEN INC.	+8.62%	168B

Other Pharmaceuticals